Metraipolis › archive › dc_ca242debc39d

Mutations in tumor signaling, metastases, and synthetic lethality establish distinct patterns — Europe PMC PMID:40758706

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/40758706
DOI: 10.1371/journal.pcbi.1013351
License (as archived): CC0-1.0
Archived: 2026-10-06T09:44:09.972Z
SHA-256 of the archived text: 07633336b02b146782fd040222f1f6a3e13058ef2ebeadd54f665578211517c0
Stable URL of this page: https://metraipolis.com/documento/dc_ca242debc39d

How to cite

Mutations in tumor signaling, metastases, and synthetic lethality establish distinct patterns — Europe PMC PMID:40758706 — Europe PMC (en), https://europepmc.org/article/MED/40758706 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_ca242debc39d (Metraipolis archive dc_ca242debc39d, sha256 07633336b02b146782fd040222f1f6a3e13058ef2ebeadd54f665578211517c0)

BibTeX

@misc{dcca242debc39d,
  title = {Mutations in tumor signaling, metastases, and synthetic lethality establish distinct patterns — Europe PMC PMID:40758706},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40758706},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_ca242debc39d; sha256 07633336b02b146782fd040222f1f6a3e13058ef2ebeadd54f665578211517c0},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/40758706. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Effective identification of oncogenic mutations is essential for diagnosis, forecasting resistance, and metastasis in remission. It is required for an optimal drug regimen. We develop a framework to discover mutations that co-exist in different oncoproteins, and those that are excluded, likely encoding oncogene-induced senescence. First, mapping the proteins onto pathways assists combinatorial drug selections and helps to detect metastases. Second, it provides the molecular basis for synthetic lethality, to date investigated at the genome level. Our pan-cancer profiles of ~60,000 tumor sequences, detect 3424 co-existing tumor-specific mutations. Mapping them onto pathways indicates that they preferentially promote specific primary tumors. We uncover metastatic mutations and provide metastatic breast-cancer markers. This work not only clarifies the mechanistic basis of intratumor mutational diversity but usefully reveals markers for metastasis in patients' genomes and introduces a novel computational framework for detecting metastasis based on tumor mutational profiles. Mapping the mutations onto pathways provides an invaluable metastasis-targeting resource, guiding drug combinations.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PLoS computational biology, 2025 (prima pubblicazione 2025-08-04).
Identificativi: PMID 40758706 · PMCID PMC12342271 · DOI 10.1371/journal.pcbi.1013351.
Descrittori MeSH principali: Neoplasms; Neoplasm Metastasis; Signal Transduction; Mutation; Synthetic Lethal Mutations.
Pagina: https://europepmc.org/article/MED/40758706 — https://doi.org/10.1371/journal.pcbi.1013351. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T09:43:20.219Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.